MTX-531, by virtue of its dual inhibitory activity against EGFR and the PI3K–mTOR pathway, offers a single-molecule strategy for overcoming multiple resistance mechanisms encountered in KRASG12C-mutant CRC. This evidence concerns the gene EGFR and colorectal carcinoma.